Statin use after diagnosis of breast cancer and survival a population-based cohort study

Epidemiology

Volumn 26, Issue 1, 2015, Pages 68-78

  Cardwell, Chris R ^a   Hicks, Blanaid M ^a   Hughes, Carmel ^a   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGLAUCOMA AGENT; AROMATASE INHIBITOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY RISK; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; BREAST TUMOR; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; FEMALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SIMVASTATIN; SURVIVAL RATE;

EID: 84937541253     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000189     Document Type: Article

References (33)

1. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem. 2009;106:975-983.
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10-19.
3. Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66:8707-8714.
4. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal. 2010;22:749-758.
5. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461-1468.
6. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011;29:585-593.
7. Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144:405-416.
8. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109:573-579.
9. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766-768.
10. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. Available at: http://bnf org/bnf/index htm. Accessed 1 April 2014.
11. World Health Organisation. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Available at: http://whocc no/. Accessed 1 April 2014.
12. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
13. C hubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013;105:1456-1462.
14. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.
15. Noble M, Wright G, Dibben C, et al. Indices of Deprivation 2004: Report to the Office of the Deputy Prime Minister. London: Neighbourhood Renewal Unit; 2004.
16. Dormuth CR, Hemmelgarn BR, Paterson JM, et al.; Canadian Network for Observational Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346:f880.
17. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-To-Treatment initiation in drug effectiveness evaluation: A comparison of methods. Am J Epidemiol. 2005;162:1016-1023.
18. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982-1998.
19. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
20. L euven E, Sianesi B. PSMATC H2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing: version 4.0.5. Available at: http://ideas. repec.org/c/boc/bocode/s432001.html. Accessed 1 April 2014.
21. A ustin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150-161.
22. A ustin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32:2837-2849.
23. Schneeweiss S, Patrick AR, Störmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 Suppl 2):S131-S142.
24. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol. 1993;137:1-8.
25. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488-495.
26. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792-1802.
27. Sendur MA, Aksoy S, Yazici O, Ozdemir NY, Zengin N, Altundag K. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol. 2014;31:835.
28. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119:137-144.
29. Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138:499-508.
30. Stewart D, Cunningham IT, Hansford D, John D, McCaig D, McLay J. General practitioners' views and experiences of over-The-counter simvastatin in Scotland. Br J Clin Pharmacol. 2010;70:356-359.
31. Yood MU, Campbell UB, Rothman KJ, et al. Using prescription claims data for drugs available over-The-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16:961-968.
32. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64-74.
33. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med. 2011;26:546-550.